10-Q: Lifecore Biomedical Reports Q3 2025 Results: Revenue Slightly Down, Net Loss Widens Amid Restructuring and Legal Costs

Lifecore Biomedical's Q3 2025 results reveal a slight revenue decrease and a significant net loss increase, impacted by restructuring, legal expenses, and the loss on the sale of assets.

Summary

• Lifecore Biomedical, Inc. reported its financial results for the third quarter of fiscal year 2025, which ended on February 23, 2025.
• Total revenues decreased slightly by 2% to $35.15 million compared to $35.70 million in the same quarter of the previous year.
• CDMO revenues decreased by 7% to $20.79 million, while HA manufacturing revenues increased by 7% to $14.37 million.
• The company reported a net loss of $14.77 million, compared to a net income of $15.63 million in the prior year's quarter.
• The operating loss was $9.03 million, compared to an operating loss of $0.90 million in the same period last year.
• The loss on sale or disposal of assets was $6.85 million, primarily due to the sale of an isolator-filler.
• Restructuring costs showed a net recovery of $0.12 million, compared to costs of $0.77 million in the prior year.
• For the nine months ended February 23, 2025, total revenues increased by 2% to $92.42 million compared to $90.38 million in the same period last year.
• The net loss for the nine-month period was $37.57 million, compared to a net income of $19.10 million in the prior year period.
• The company's cash and cash equivalents were $5.42 million as of February 23, 2025, with approximately $25.5 million available for borrowing under the Revolving Credit Facility.
• The company is addressing material weaknesses in internal control over financial reporting and plans to implement a new ERP system by the second half of fiscal year 2026.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased net loss, decreased revenues in the CDMO segment, and ongoing legal and regulatory challenges. However, there are some positive aspects, such as the increase in HA manufacturing revenues and the company's efforts to address internal control weaknesses.

Positives

• HA manufacturing revenues increased by 7% for the quarter and 13% for the nine months ended February 23, 2025.
• The company anticipates recording an additional reversal of $2.5 million related to a historical lease obligation in the fourth quarter of fiscal 2025.
• The company has approximately $25.5 million available for borrowing under the Revolving Credit Facility.
• The company is taking steps to remediate material weaknesses in internal control over financial reporting.

Negatives

• CDMO revenues decreased by 7% for the quarter.
• The company reported a net loss of $14.77 million for the quarter, compared to a net income of $15.63 million in the prior year's quarter.
• The operating loss was $9.03 million, compared to an operating loss of $0.90 million in the same period last year.
• A $6.85 million loss on the sale of assets, primarily an isolator-filler, impacted the bottom line.
• SG&A expenses increased due to higher stock-based compensation and litigation expenses.
• The company's disclosure controls and procedures were not effective as of February 23, 2025, due to material weaknesses in internal control over financial reporting.
• The net loss for the nine-month period was $37.57 million, compared to a net income of $19.10 million in the prior year period.

Risks

• The company's ability to successfully enact its business strategies, including installation, capacity generation, and attracting demand for its services, is a risk.
• The impact of inflation on the company's business and financial condition is a risk.
• Changes in business conditions and general economic conditions, including rising interest rates and global trade tensions, pose risks.
• The company faces risks related to government regulations affecting its business and the timing of regulatory approvals.
• The company's ability to expand its relationship with existing customers or attract new customers is a risk.
• The company is involved in various legal proceedings and claims, including an investor dispute, a class action complaint, and an SEC subpoena.
• Material weaknesses in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information.

Future Outlook

The company anticipates receiving the FDA's response and resolving the inspection findings during the fourth quarter of fiscal 2025 and expects to finish incurring expenses under the restructuring plan by the end of fiscal year 2025.

Industry Context

The company operates in the CDMO and HA manufacturing industries, which are subject to competition, regulatory requirements, and market demand. The company's performance is influenced by its ability to secure contracts, manage costs, and maintain quality standards.

Comparison to Industry Standards

• It is difficult to compare Lifecore's results directly to industry standards without knowing the specific mix of services and products they offer compared to their peers.
• However, companies like Catalent, Thermo Fisher Scientific (specifically their CDMO segment), and Lonza are major players in the CDMO space.
• These companies often have higher revenue due to their scale and broader service offerings.
• In the HA manufacturing space, companies like Fidia Farmaceutici S.p.A. and Shiseido may be considered comparables, but their overall business models may differ significantly from Lifecore's.
• Lifecore's gross profit margin of 28.0% is lower than some of the larger CDMOs, which can achieve margins of 30-40% or higher due to economies of scale and specialized services.
• The net loss reported by Lifecore is a concern, as many established CDMOs and HA manufacturers are typically profitable.

Legal Proceedings

• The company is involved in an investor dispute filed by 22NW Fund, L.P.
• The company is involved in a putative class action complaint filed on behalf of stockholders.
• The company is responding to a subpoena issued by the Chicago Regional Office of the SEC.
• The company is involved in a legal proceeding related to a historical lease obligation of the Curation Foods business.
• The company is involved in compliance matters related to the Yucatan Acquisition.

Related Party Transactions

• Alcon has been designated as a related party due to its significant influence over the company as a major customer and creditor.
• The company has customary current financial positions with Alcon, including accounts receivable, contract liabilities, and revenue.
• Alcon has provided the company guaranteed contractual minimum purchasing commitments.
• Alcon provided cash advances to the company to purchase and install Alcon-owned equipment.
• Alcon has a significant noncurrent contract liability with the company, representing a prepayment.
• The company has a Term Loan Credit Facility with Alcon.
• Alcon purchased equipment that it is leasing back to the company.

Stakeholder Impact

• Shareholders are impacted by the company's net loss and the ongoing legal proceedings.
• Employees are impacted by the company's restructuring efforts and changes in internal control over financial reporting.
• Customers are impacted by the company's ability to maintain quality standards and meet demand.
• Creditors are impacted by the company's ability to comply with financial covenants.
• Suppliers are impacted by the company's ability to manage costs and maintain relationships.

Next Steps

• The company anticipates receiving the FDA's response and resolving the inspection findings during the fourth quarter of fiscal 2025.
• The company plans to complete implementation and testing of its control environment and risk assessment procedures during the fourth quarter of fiscal 2025.
• The company plans to complete the design and implementation of the ERP in the second half of fiscal year 2026.
• The company plans to test and subsequently monitor the design and operating effectiveness of internal controls over financial reporting immediately following the implementation of the ERP.

Key Dates

Keywords

CDMO, HA manufacturing, financial results, net loss, revenue, Lifecore Biomedical, Q3 2025, restructuring, legal proceedings, internal control